Clinical usefulness of bone markers in prostate cancer with bone metastasis

Denosumab

(2013) Allan Lipton et al.   Current Opinion in Supportive and Palliative Care

Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis

(2011) Kouji Izumi et al.   BJU INTERNATIONAL

Dasatinib combined with docetaxel for castration-resistant prostate cancer

(2011) John C. Araujo et al.   CANCER

Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis

(2011) Naoto Kamiya et al.   International Journal of Clinical Oncology

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

(2011) Matthew R Smith et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer

(2011) F. Dayyani et al.   JNCI-Journal of the National Cancer Institute

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

(2011) Evan Y. Yu et al.   UROLOGY

Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer

(2010) S. Rajpar et al.   ANNALS OF ONCOLOGY

Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro

(2010) Patrick Garnero et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer

(2010) Philip J. Saylor et al.   JOURNAL OF UROLOGY

Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer

(2010) Fred Saad et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis

(2010) Naoto Kamiya et al.   UROLOGY

Bone-marker levels in patients with prostate cancer: potential correlations with outcomes

(2010) Fred Saad et al.   Current Opinion in Supportive and Palliative Care

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

(2008) Allan Lipton et al.   CANCER

Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions

(2008) Robert Coleman et al.   CANCER TREATMENT REVIEWS

Molecular mechanisms and treatment of bone metastasis

(2008) Gregory A. Clines et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer

(2008) Choichiro Ozu et al.   INTERNATIONAL JOURNAL OF UROLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY